Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 209

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

The future of engineered immune cell therapies

Open access
Irvine, Darrell J., Maus, Marcela V., Mooney, David J., Wong, Wilson W. · 2022 · Science

Abstract

Immune cells are being engineered to recognize and respond to disease states, acting as a “living drug” when transferred into patients. Therapies based on engineered immune cells are now a clinical reality, with multiple engineered T cell therapies approved for treatment of hematologic malignancies. Ongoing preclinical and clinical studies are testing diverse strategies to modify the fate and function of immune cells for applications in cancer, infectious disease, and beyond. Here, we discuss current progress in treating human disease with immune cell therapeutics, emerging strategies for immune cell engineering, and challenges facing the field, with a particular emphasis on the treatment of cancer, where the most effort has been applied to date.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/science.abq6990

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 209

Metadata

Authors
Irvine, D. J., Maus, M. V., Mooney, D. J., & Wong, W. W.
Venue
Science
Published
2022-11-25
Volume
378
Issue
6622
Pages
853-858
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W4310251912
Cited by
209
References
12
FWCI
14.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The future of engineered immune cell therapies. https://app.cochat.ai/papers/10.1126/science.abq6990
The paper
Irvine, D. J., Maus, M. V., Mooney, D. J., & Wong, W. W. (2022). The future of engineered immune cell therapies. Science. https://doi.org/10.1126/science.abq6990

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.